CCK-JMV-180 acts as an antagonist of the CCKA receptor in the human IMR-32 neuroblastoma cell line.

Abstract

[125I]Cholecystokinin-8-S (CCK-8-S) bound to a single class of saturable binding sites on the human neuroblastoma cell line IMR-32 (KD = 4 +/- 1.5 nM, Bmax = 10,500 +/- 3,500 sites/cell (n = 6)). These binding sites were of the CCKA type, as demonstrated by the differential inhibition of the binding of [125I]CCK-8-S and CCK-8-S-induced 45Ca2+ efflux by the specific CCKA antagonist SR 27897 and the specific CCKB antagonist PD 134,308. CCK-JMV-180, an analogue of CCK-8-S which has been shown to activate 45Ca2+ efflux in rat cells in a manner similar to CCK-8-S, acted as a potent antagonist of CCK-8-S-induced 45Ca2+ efflux (IC50 = 50 nM) and inhibited [125I]CCK-8-S binding to IMR-32 cells (IC50 = 1.7 nM). These results show that, unlike its CCK-like effect in various animal systems, CCK-JMC-180 acts as an antagonist of CCKA receptors in the human neuroblastoma cell line IMR-32.

• Authors: P Schaeffer, V Prabonnaud, M Roux, D Gully, J M Herbert
• Journal: FEBS letters (FEBS Lett) Vol. 354 Issue 2 Pg. 203-6 (Nov 07 1994) ISSN: 0014-5793 [Print] England
• PMID: 7957924 (Publication Type: Journal Article)

Chemical References

• Calcium Radioisotopes
• Receptors, Cholecystokinin
• JMV 180
• Sincalide

Topics

• Calcium Radioisotopes (metabolism)
• Humans
• Kinetics
• Neuroblastoma (metabolism)
• Receptors, Cholecystokinin (antagonists & inhibitors, metabolism)
• Sincalide (analogs & derivatives, metabolism, pharmacology)
• Tumor Cells, Cultured